Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects

European Journal of Clinical Investigation

Volumn 28, Issue 12, 1998, Pages 971-979

  Tonstad, S ^a,c   Joakimsen, O ^b   Stensland Bugge, E ^b   Ose, L ^a   Bonaa K H ^b   Leren, T P ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carotid artery; Familial hypercholesterolaemia; Low density lipoprotein receptor; Mutations; Ultrasonography

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ARTERY; CAROTID ARTERY BIFURCATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; HUMAN; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; PRIORITY JOURNAL; XANTHOMA;

EID: 0032457124     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00399.x     Document Type: Article

References (45)

1. 1 Ose L, Tonstad S. The detection and management of dyslipidaemia in children and adolescents. Acta Pædiatr 1995;84:1213-5.
2. 2 Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA 1990;264:3007-12.
3. 3 Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-21.
4. 4 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
5. 5 Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991;11:1245-9.
6. 6 Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995;75:455-9.
7. 7 Sidhu PS, Naoumova RP, Maher VMG et al. The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. J Cardiovasc Risk 1996;3:61-7.
8. 8 Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11:290-7.
9. 9 Tonstad S, Joakimsen O, Stensland-Bugge E et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and controls. Arterioscler Thromb Vasc Biol 1996;16:984-91.
10. 10 Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-9.
11. 11 Gylling H, Aalto-Setala K, Kontula K, Miettinen TA. Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia. Arterioscler Thromb 1991;11:1368-75.
12. 12 Gudnason V, Day INM, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler Thromb 1994;14: 1717-22.
13. 13 Jeenah M, September W, van Roggen FG, de Villiers W, Seftel H, Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1993;98:51-8.
14. 14 Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-66.
15. 15 Nygård O, Vollset SE, Refsum H et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995;274:1526-33.
16. 16 Ernst E. Plasma fibrinogen an independent cardiovascular risk factor. J Intern Med 1990;227:365-72.
17. 17 Leren TP, Solberg K, Rødningen OK, Tonstad S, Ose L. Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis 1994;111:175-82.
18. 18 Sundvold H, Solberg K, Tonstad S et al. A common missense mutation (C210G) in the LDL receptor gene among Norwegian familial hypercholesterolemia subjects. Hum Mutat 1996;7:70-1.
19. 19 Leren TP, Sundvold H, Rødningen OK et al. Screening for known mutations in the LDL receptor gene causing familial hypercholesterolemia. Hum Genet 1995;95:671-6.
20. 20 Sun X-M, Patel DD, Bhatnagar D, Knight BL, Soutar AK. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb Vasc Biol 1995;15:219-27.
21. 21 Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypcholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest 1995;25:967-73.
22. 22 Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994;14:1066-74.
23. 23 Eiklid K, Leren TP. Genotyping of apolipoprotein E. J Norw Med Ass 1993;113:1885.
24. 24 Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989;35:1921-7.
25. 25 Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993;39:263-71.
26. 26 Thelle DS, Førde OH, Try K, Lehmann EH. The Tromsø Heart Study. Acta Med Scand 1976;200:107-18.
27. 27 Bønaa KH, Thelle DS. Association between blood pressure and serum lipids in a population. Circulation 1991;83: 1305-14.
28. 28 Stensland-Bugge E, Bønaa KH, Joakimsen O. Reproducibility of ultrasonographically determined intima-media thickness is dependent on arterial wall thickness. The Tromsø Study. Stroke 1997;28:1972-80.
29. 29 Wendelhag I, Gustavsson T, Suurkula M, Berglund G, Wikstrand J. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analysing system. Clin Physiol 1991;11: 565-77.
30. 30 Joakimsen O, Bønaa KH, Stensland-Bugge E. Reproducibility of ultrasound assessment of carotid plaque occurrence, thickness, and morphology. The Tromsø Study. Stroke 1997;28:2201-7.
31. 31 Wendelhag I, Wiklund O, Wikstrand J. Arterial wall thickness in familial hypercholesterolemia. Ultrasound measurement of intima-media thickness in the common carotid artery. Arterioscler Thromb 1992;12:70-7.
32. 32 Bradford RH, Shear CL, Chremos AN et al. Expanded clinical evaluation of lovastatin (EXCEL) Study results. Arch Intern Med 1991;151:43-9.
33. 33 Furberg CD, Adams HP, Applegate WB et al. for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atheroslcerosis and cardiovascular events. Circulation 1994;90:1679-87.
34. 34 Hodis HN, Mack WJ, LaBree L et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy. Ann Intern Med 1996;124:548-56.
35. 35 National Cholesterol Education Program. Report of the Expert Panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89:525-84.
36. 36 Mbewu AD, Bhatnagar D, Durrington PN et al. Serum lipoprotein (a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991;11:940-6.
37. 37 Ferrieres J, Lambert J, Lussier-Cacan S, Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995;92:290-5.
38. 38 Gagne C, Moorjani S, Brun D, Toussaint M, Lupien PJ. Heterozygous familial hypercholesterolemia. Relationship between plasma lipids, lipoproteins, clinical manifestations and ischaemic heart disease in men and women. Atherosclerosis 1979;34:13-24.
39. 39 Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond G, Davis CE for the ARIC investigators. Association of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994;14:1098-104.
40. 40 Sprecher DL, Daniels SR. Rational approach to pharmacologic reduction of cholesterol levels in children. J Pediatr 1996;129:4-7.
41. 41 McCully KS. Homocysteine and vascular disease. Nature Med 1996;2:386-9.
42. 42 Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
43. 43 Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 1993;13:661-8.
44. 44 Willeit J, Kiechl S, Santer P et al. Lipoprotein (a) and asymptomatic carotid artery disease. Stroke 1995;26: 1582-7.
45. 45 Tonstad S, Leren TP, Sivertsen M, Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol 1995;15:1009-14.